E
Eldar Topuzov
Publications - 15
Citations - 1921
Eldar Topuzov is an academic researcher. The author has contributed to research in topics: Ramucirumab & Cancer. The author has an hindex of 5, co-authored 10 publications receiving 1633 citations.
Papers
More filters
Journal ArticleDOI
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,G. Aprile,David Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Zalcberg,John Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M. Liepa,Ling Gao,Jonathan D. Schwartz,Josep Tabernero +24 more
TL;DR: Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, and validate VEGFR-2 signalling as an important therapeutic target in advanced Gastric cancer.
Journal ArticleDOI
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
Elena Elez,Ilona Kocáková,T. Höhler,Uwe M. Martens,Carsten Bokemeyer,E. Van Cutsem,Bohuslav Melichar,Martin Šmakal,T. Csőszi,Eldar Topuzov,Rashida Orlova,Sergei Tjulandin,Fernando Rivera,J. Straub,Rolf Bruns,Sonia Quaratino,Josep Tabernero +16 more
TL;DR: The primary PFS end point was not met, although predefined exploratory biomarker analyses identified subgroups of patients in whom abituzumab may have benefit, and the tolerability of abitzumab combined with cetuximab and irinotecan was acceptable.
Journal ArticleDOI
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Charles S. Fuchs,Josep Tabernero,Jiří Tomášek,Ian Chau,Bohuslav Melichar,Howard Safran,Mustapha Tehfe,Dumitru Filip,Eldar Topuzov,Luis Schlittler,Anghel Adrian Udrea,William Campbell,Stephen Brincat,Michael Emig,Symantha Melemed,Rebecca R. Hozak,David Ferry,C. William Caldwell,Jaffer A. Ajani +18 more
TL;DR: REGARD exploratory analyses did not identify a strong potentially predictive biomarker of ramucirumab efficacy; however, statistical power was limited.
Journal ArticleDOI
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW
Kei Muro,Jae Yong Cho,György Bodoky,Chanchal Goswami,Yee Chao,Lucas Vieira dos Santos,Yasuhiro Shimada,Eldar Topuzov,Eric Van Cutsem,Josep Tabernero,John Zalcberg,Ian Chau,Stefano Cascinu,Rebecca Cheng,Yanzhi Hsu,Michael Emig,Mauro Orlando,Charles S. Fuchs +17 more
TL;DR: Exploratory subgroup analyses were described to assess the efficacy and safety of ramucirumab in REGARD and RAINBOW in young and elderly patients.
Journal ArticleDOI
REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.
Charles S. Fuchs,Jiri Tomasek,Jae Yong Cho,Gianluca Tomasello,Chanchal Goswami,Lucas Vieira dos Santos,Giuseppe Aprile,David Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Zalcberg,Ian Chau,Josep Tabernero,Yanzhi Hsu,Jonathan D. Schwartz,Minori Koshiji,Howard Safran +17 more
TL;DR: In this article, the REGARD trial demonstrated significant improvements in overall survival (OS), progression free survival (PFS), and disease control rates in pts receiving RAM, a human IgG1 recep...